[{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"8934f0cb-e0b1-4008-8421-763be12314d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383196","created_at":"2022-05-20T18:58:19.196Z","updated_at":"2024-07-02T16:35:02.611Z","phase":"Phase 1/2","brief_title":"Onvansertib + Paclitaxel In TNBC","source_id_and_acronym":"NCT05383196","lead_sponsor":"Antonio Giordano, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • onvansertib (PCM-075)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 02/15/2026","primary_completion_date":" 02/15/2026","study_txt":" Completion: 02/15/2029","study_completion_date":" 02/15/2029","last_update_posted":"2024-05-20"},{"id":"661d65c0-b705-4f26-9720-4dc72aa20c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT06106308","created_at":"2023-10-30T16:12:32.775Z","updated_at":"2024-07-02T16:35:06.108Z","phase":"Phase 2","brief_title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","source_id_and_acronym":"NCT06106308","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-03"},{"id":"78a25275-44d9-4dd0-a5b4-65a103b2a67e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03829410","created_at":"2021-01-17T17:16:00.145Z","updated_at":"2024-07-02T16:35:16.847Z","phase":"Phase 1/2","brief_title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation","source_id_and_acronym":"NCT03829410","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/06/2019","start_date":" 05/06/2019","primary_txt":" Primary completion: 01/29/2024","primary_completion_date":" 01/29/2024","study_txt":" Completion: 01/29/2024","study_completion_date":" 01/29/2024","last_update_posted":"2024-03-01"},{"id":"dad0c4dd-09a2-4451-b67d-87c0d6cf6455","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446793","created_at":"2021-01-18T21:23:54.941Z","updated_at":"2024-07-02T16:35:19.823Z","phase":"","brief_title":"Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04446793","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-12"},{"id":"7aeffcc1-8575-4ac7-bef5-83f3bb3a65fa","acronym":"ONSEMBLE","url":"https://clinicaltrials.gov/study/NCT05593328","created_at":"2022-10-25T13:56:27.583Z","updated_at":"2024-07-02T16:35:23.267Z","phase":"Phase 2","brief_title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation","source_id_and_acronym":"NCT05593328 - ONSEMBLE","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-17"}]